Status: Recruiting
A Phase 2 Study of NT-101 Topical in Patients With Wet AMD
This phase 2 trial is a randomized, double-blind, placebo-controlled, multicenter study in patients with wet AMD to assess the efficacy and safety of NT-101 topical ophthalmic solution (0.20 mM) administered into the study eye twice daily (BID) for 12 weeks.
Participants needed: 66
Trial details
Phase: Phase 2Age: 50+Biological sex: AllType: InterventionalSponsor: NexThera Co., Ltd.Updated: Sep 16, 2026Locations: 3
Eligibility criteria
Subject who is male or female ≥ 50 years of age at Screening. [+21]
Subject who has the following illness or abnormal laboratory test values at [+30]